Lumpie,

Thanks again for the information. I will review and ask MO to help me get into a vaccine clinical trial

found another one

OP-1250 is a small molecule Complete Estrogen Receptor ANtagonist (CERAN). OP-1250 potently competes with the endogenous activating estrogenic ligand 17-beta estradiol for binding in the ligand binding pocket. OP-1250 blocks estrogen-driven transcriptional activity, inhibits estrogen-driven breast cancer cell growth, and induces degradation of the estrogen

https://clinicaltrials.gov/ct2/show/NCT04505826?term=Sarah+Cannon&recrs=ab&cond=Breast+Cancer&draw=2&rank=2

dee

Targeting Breast Cancer Cells and Leaving Healthy Cells Unscathed

...Now scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill multiplying human breast cancer cells by selectively attacking the core of their cell division machinery. The method, only tested on lab-grown and patient-derived cancer cells, could advance efforts to find drugs that kill breast cancer cells in a subset of patients...

The research team looked for cell division mechanisms specific to cancer cells in a variety of lab-grown cells. During their search, they encountered a line of human breast cancer cells that are very dependent on cell structures called centrioles to divide and survive....

Further observations revealed that the centriole-dependent breast cancer cells had a section of genome that had been abnormally copied many times, an alteration found in about 9% of breast cancers. The researchers observed the genes encoded in the highly copied region and found a gene that was producing high levels of a protein called TRIM37 shown to control centrosomes...

They used a PLK4 inhibitor known to disrupt proteins that make centrioles, which interfered with TRIM37. When they added the drug to the lab-grown cancer cells with normal TRIM37 levels, they found that the cells were able to divide, even though the drug had removed the cell's centrioles. When the drug was added to breast cancer cells with high TRIM37 levels the cells were not able to divide and most cells stopped growing or died.

"The idea would be to identify tumors with high levels of TRIM37 and use a PLK4 inhibitor to selectively kill cancer cells and leave healthy cells relatively unharmed," explained Holland.

https://www.genengnews.com/news/targeting-breast-c...

paper: https://www.nature.com/articles/s41586-020-2690-1....

Olma,

Really interesting idea. As with a lot of these great ideas, though, it's not ready for prime time (although a lot of us are!)

Exercise and bone loss. Interesting article on exercise/bone loss in premenopause vs menopause. I wonder if post menopause needs to do more or different exercise to achieve same benefit. Also, which drugs were patients using? I still plan on exercising!! Trying to figure out how to get full article. https://www.practiceupdate.com/journalscan/73090/2/1?elsca1=emc_enews_daily-digest&elsca2=email&elsca3=practiceupdate_onc&elsca4=oncology&elsca5=newsletter&rid=NDg2NTE3NjI4ODEyS0&lid=10332481

I agree Saulius, Sounds so interesting I am tempted to buy access.

thanks for this tip, Cure-ious

Verzenio [reduces risk of] Recurrence and Metastasis of Early Breast Cancer

For people with high-risk HR-positive/HER2-negative early breast cancer, the oral medication Verzenio (abemaciclib) reduced the likelihood of recurrence by 25% when combined with adjuvant (post-surgery) hormone therapy, researchers reported at the European Society for Medical Oncology's ESMO Virtual Congress 2020 and in the Journal of Clinical Oncology.

If approved for this indication, Verzenio has the potential to set a new standard of care, according to lead study investigator Stephen Johnston, MD, PhD, a professor of breast cancer medicine at the Royal Marsden NHS Foundation Trust in London. It is "potentially one of the most notable treatment advances in the last two decades for this population of breast cancer patients," he said in a press release...

Between July 2017 and August 2019, Johnston and colleagues recruited 5,637 people with high-risk HR-positive/HR-negative early breast cancer from 38 countries for a Phase III study known as MonarchE...

At the two-year mark, 7.8% of the participants taking Verzenio had experienced a recurrence compared with 11.3% of the participants not taking Verzenio—a 25% reduction in risk.

Verzenio plus hormone therapy also improved distant relapse-free survival, a measure of the time to metastasis to another part of the body. At the two-year mark, 6.4% of the participants taking Verzenio and 9.7% of the participants not taking the drug had experienced metastasis—a 28% risk reduction...

Even though the study has not yet been completed—final results are projected for delivery in June 2027—Giuseppe Curigliano, MD, PhD, the chair of ESMO's guidelines committee, is optimistic. "This is a very important trial, and the findings will change practice," he said in an ESMO press release.

https://www.cancerhealth.com/article/verzenio-prev...

Experimental Cancer Treatment Destroys Cancer Cells [in mice] Without Using Any Drugs

One of the latest methods pioneered by scientists to treat cancer uses a Trojan horse sneak attack to prompt cancer cells to self-destruct – all without using any drugs.

Key to the technique is the use of a nanoparticle coated in a specific amino acid called L-phenylalanine, one of several such acids that cancer cells rely on to grow. L-phenylalanine isn't made by the body, but absorbed from meat and dairy products.

In tests on mice, the nanoparticle – called Nano-pPAAM or Nanoscopic phenylalanine Porous Amino Acid Mimic – killed cancer cells specifically and effectively, posing as a friendly amino acid before causing the cells to destroy themselves.

The self-destruction mode is triggered as the nanoparticle puts production of certain chemicals known as reactive oxygen species (ROS) into overdrive. It's enough to bring down the cancer cells while leaving neighbouring, healthy cells intact...

Nano-pPAAM was shown to kill around 80 percent of breast, skin, and gastric cancer cells in mice, about on a par with current chemotherapy drugs (but without all the side effects of course). While dangerous to cancer cells, it's based on a silica nanoparticle classed as safe to humans by US food regulators.

https://www.sciencealert.com/a-new-cancer-treatmen...

Predictive Analytics Detects Breast Cancer Spread with 90% Accuracy

September 28, 2020 - A predictive analytics method was able to detect with 90 percent accuracy which stage 0 breast cancers [DCIS] are likely to spread and recur, according to a study published in the American Journal of Physiology-Cell Physiology...

The team stained these tissue samples so that the proteins of interest would fluoresce under the microscope. Then, using a computer vision application, researchers created a library of microscope images associated with either aggressive or non-aggressive ductal carcinoma in situ (DCIS) based on what had happened to that patient.

Researchers then showed the program roughly 100 micrographs it hadn't seen before, known as holdout images, to see how well it could accurately predict whether that patient's cancer was likely to recur...

The program is now able to correctly identify aggressive and non-aggressive disease 96 percent of the time, the researchers noted.

"That's pretty impressive when you consider that a human looking at these images would get the answer right about 70 percent of the time," Petty said. "And we've continued to work on reducing the level of false negatives."

The tool also reported false positives in four percent of cases, meaning it identified aggressive disease in patients who did not experience recurrence.

https://healthitanalytics.com/news/predictive-anal...